Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma

  • Authors:
    • Sun‑Ae Kim
    • Kyung‑Hwa Lee
    • Dong Hoon Lee
    • Joon Kyoo Lee
    • Sang Chul Lim
    • Young‑Eun Joo
    • Ik‑Joo Chung
    • Myung‑Giun Noh
    • Tae Mi Yoon
  • View Affiliations

  • Published online on: July 2, 2019     https://doi.org/10.3892/ijo.2019.4836
  • Pages: 513-526
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The receptor tyrosine kinase, recepteur d'origine nantais (RON), is known to be associated with the progression, metastasis, and prognosis of various types of cancers. Nevertheless, the role of RON in human oral squamous cell carcinoma (OSCC) is unclear. This study evaluated whether RON affects oncogenic behavior, oncogenic signaling pathways, and clinical outcomes, including survival, in human OSCC. Reverse transcription‑PCR, quantitative PCR, western blotting and immunohistochemical staining were used to determine mRNA and protein expression levels of RON. Cell invasion, migration and apoptosis assays were used to assess the functional effects of small interfering RNA‑mediated knockdown of RON or snail family transcriptional repressor 2 (SLUG). RON knockdown suppressed tumor cell invasion and migration and enhanced apoptosis in human OSCC cells. RON knockdown also decreased the phosphorylation of MAPK signaling proteins, such as ERK1/2, JNK and p38. In addition, RON knockdown suppressed the expression of the epithelial mesenchymal transition (EMT)‑related transcription factor, SLUG. SLUG knockdown blocked the enhancement of cell invasion and migration induced by macrophage‑stimulation protein (MSP)‑mediated RON activation in OSCC cells. The cell morphology was changed to spindle‑like shape under MSP‑mediated RON activation in OSCC cells. RON was overexpressed in both fresh and paraffin‑embedded human OSCC tissues. Taken together, these results indicate that RON contributed to tumor progression by regulating the EMT‑related factor, SLUG, and the MAPK pathway in OSCC. This study may provide a theoretical basis for the application of RON‑targeting agents, currently being studied in various cancer fields, for the treatment of OSCC.

References

1 

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al Global Burden of Disease Cancer Collaboration: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, et al: National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck Cancers (Version 1). 2018, http://www.nccn.orgurisimplewww.nccn.org. Accessed February 15, 2018.

4 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Wincheser DP: American Joint Committee on Cancer-Cancer Staging Manual. 8th edition. Springer; New York, NY: 2018

5 

Pentenero M, Gandolfo S and Carrozzo M: Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: A review of the literature. Head Neck. 27:1080–1091. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Wang MH, Wang D and Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 24:1291–1300. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ and Comoglio PM: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13:3524–3532. 1994. View Article : Google Scholar : PubMed/NCBI

8 

Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL and Friezner Degen SJ: The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J Clin Invest. 103:1277–1285. 1999. View Article : Google Scholar : PubMed/NCBI

9 

Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR, Wang MH, Kaestner KH and Degen SJ: Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest. 108:567–576. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Chen Q, Seol DW, Carr B and Zarnegar R: Co-expression and regulation of Met and Ron proto-oncogenes in human hepato-cellular carcinoma tissues and cell lines. Hepatology. 26:59–66. 1997.PubMed/NCBI

11 

Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P and Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene. 16:2927–2933. 1998. View Article : Google Scholar : PubMed/NCBI

12 

Lin HS, Berry GJ, Fee WE Jr, Terris DJ and Sun Z: Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg. 130:311–316. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 12:273–281. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Lee WY, Chen HH, Chow NH, Su WC, Lin PW and Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 11:2222–2228. 2005. View Article : Google Scholar : PubMed/NCBI

15 

Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ and Ellis LM: Tyrosine kinase receptor RON in human pancreatic cancer: Expression, function, and validation as a target. Cancer. 109:1030–1039. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH and Bishop JM: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA. 104:7570–7575. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, et al: RON (MST1R) is a novel prognostic marker and therapeut-ictarget for gastroesophageal adenocarcinoma. Cancer Biol Ther. 12:9–46. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Bieniasz M, Radhakrishnan P, Faham N, De La OJP and Welm AL: Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts. Clin Cancer Res. 21:5588–5600. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS, Zhang RW and Wang MH: The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Mol Cancer. 10:822011. View Article : Google Scholar : PubMed/NCBI

21 

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, et al: Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 8:e540142013. View Article : Google Scholar : PubMed/NCBI

22 

Yoon TM, Kim SA, Park YL, Lee KH, Sung MW, Lee JK, Lim SC, Chung IJ and Joo YE: Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer. Head Neck. 35:1106–1113. 2013. View Article : Google Scholar

23 

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: American Joint Committee on Cancer-Cancer Staging Manual. 7th edition. Springer; New York, NY: 2010

24 

Xu XM, Wang D, Shen Q, Chen YQ and Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 23:8464–8474. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Cho SB, Park YL, Song YA, Kim KY, Lee GH, Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, et al: Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol Rep. 26:1581–1586. 2011.PubMed/NCBI

26 

Santamaria PG, Moreno-Bueno G, Portillo F and Cano A: EMT: Present and future in clinical oncology. Mol Oncol. 11:718–738. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Wang D, Shen Q, Chen YQ and Wang MH: Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesen-chymal transition: Roles of the RON receptor tyrosine kinase. Oncogene. 23:1668–1680. 2004. View Article : Google Scholar : PubMed/NCBI

29 

Xiangming X, Yun Q, Guoliang Z, Jianjiang L and Lisong T: Mechanisms of RON-mediated epithelial-mesenchymal transition in MDCK cells through the MAPK pathway. Braz J Med Biol Res. 44:634–641. 2011.PubMed/NCBI

30 

Wang D, Shen Q, Xu XM, Chen YQ and Wang MH: Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells. Carcinogenesis. 26:27–36. 2005. View Article : Google Scholar

31 

Côté M, Miller AD and Liu SL: Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun. 360:219–225. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Lee CT, Chow NH, Su PF, Lin SC, Lin PC and Lee JC: The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 51:1268–1274. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Song YA, Park YL, Kim KY, Myung E, Chung CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathol Int. 62:127–136. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Han WL, Li WD, Hu J, Rusidanmu A, Chen LF, Shen L and Zheng SS: Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance. Chin Med J (Engl). 125:1110–1114. 2012.

35 

Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zucconi A, Santaguida S, Zannoni G, Scambia G and Ferlini C: Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. Gynecol Oncol. 111:237–243. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, Chen MH and Yeh CN: MET-RON dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-RON upregulation indicates worse prognosis for intra-hepatic cholan-giocarcinoma patients. Oncol Rep. 40:1411–1421. 2018.PubMed/NCBI

37 

Ling Y, Kuang Y, Chen LL, Lao WF, Zhu YR, Wang LQ and Wang D: A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells. Oncotarget. 8:39101–39116. 2017. View Article : Google Scholar : PubMed/NCBI

38 

Krishnaswamy S, Mohammed AK, Tripathi G, Alokail MS and Al-Daghri NM: Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing. BMC Cancer. 17:7382017. View Article : Google Scholar : PubMed/NCBI

39 

Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z, et al: A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene. 35:3249–3259. 2016. View Article : Google Scholar :

40 

Krishnaswamy S, Bukhari I, Mohammed AK, Amer OE, Tripathi G, Alokail MS and Al-Daghri NM: Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines. Gene. 679:335–340. 2018. View Article : Google Scholar : PubMed/NCBI

41 

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, et al: A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget. 8:69651–69662. 2017. View Article : Google Scholar : PubMed/NCBI

42 

Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, et al: A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 23:2405–2413. 2017. View Article : Google Scholar :

43 

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, et al: Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 35:442–450. 2017. View Article : Google Scholar : PubMed/NCBI

44 

Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R and Wang MH: Efficacy of anti-RON antibody Zt/g4-drug maytan-sinoid conjugation (anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res. 20:6045–6058. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Chen JF, Yu BX, Yu R, Ma L, Lv XY, Cheng Y and Ma Q: Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncol Rep. 37:721–728. 2017. View Article : Google Scholar : PubMed/NCBI

46 

Suthe SR, Yao HP, Weng TH, Hu CY, Feng L, Wu ZG and Wang MH: RON receptor tyrosine kinase as a therapeutic target for eradication of triple-negative breast cancer: Efficacy of anti-RON ADC Zt/g4-MMAE. Mol Cancer Ther. 17:2654–2664. 2018. View Article : Google Scholar : PubMed/NCBI

47 

Yao HP, Feng L, Weng TH, Hu CY, Suthe SR, Mostofa AGM, Chen LH, Wu ZG, Wang WL and Wang MH: Preclinical efficacy of anti-RON antibody-drug conjugate Zt/g4-MMAE for targeted therapy of pancreatic cancer overexpressing RON receptor tyrosine kinase. Mol Pharm. 15:3260–3271. 2018. View Article : Google Scholar : PubMed/NCBI

48 

Ruiz-Torres SJ, Benight NM, Karns RA, Lower EE, Guan JL and Waltz SE: HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling. Oncotarget. 8:58918–58933. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Ekiz HA, Lai SA, Gundlapalli H, Haroun F, Williams MA and Welm AL: Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. Oncoimmunology. 7:e14802862018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2019
Volume 55 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kim, S., Lee, K., Lee, D., Lee, J., Lim, S., Joo, Y. ... Yoon, T. (2019). Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. International Journal of Oncology, 55, 513-526. https://doi.org/10.3892/ijo.2019.4836
MLA
Kim, S., Lee, K., Lee, D., Lee, J., Lim, S., Joo, Y., Chung, I., Noh, M., Yoon, T."Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma". International Journal of Oncology 55.2 (2019): 513-526.
Chicago
Kim, S., Lee, K., Lee, D., Lee, J., Lim, S., Joo, Y., Chung, I., Noh, M., Yoon, T."Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma". International Journal of Oncology 55, no. 2 (2019): 513-526. https://doi.org/10.3892/ijo.2019.4836